# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs' Hedge Fund Trend Monitor highlights concentration in mega-caps, with optimism in AI and health care.
Oyster Point Pharma (NASDAQ:OYST) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $...
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter.
Upgrades
Chardan Capital analyst Daniil Gataulin downgrades Oyster Point Pharma (NASDAQ:OYST) from Buy to Neutral and lowers the pric...
SVB Leerink raised the price target on Cigna Corporation (NYSE: CI) from $305 to $335. Cigna shares rose 0.7% to close at ...
Gainers
Piper Sandler analyst Joseph Catanzaro downgrades Oyster Point Pharma (NASDAQ:OYST) from Overweight to Neutral and lowers th...
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recor...